Hormone Receptors and Epithelial Ovarian Cancer : Recent Advances in Biology and Treatment Options
Epithelial ovarian cancer (EOC) is a significant cause of cancer-related mortality in women. Despite advances in diagnosis and treatment, EOC remains a challenging disease to manage, and the 5-year survival rate is still poor. The role of hormone receptors (HRs) in EOC carcinogenesis and prognosis has been actively explored; however, the role of hormone therapy (HT) in the treatment of these tumors is not well established. Most available data on HT mainly come from retrospective series and small early clinical trials. Several of these studies suggest that HT may have a role in adjuvant, maintenance therapy, or in the case of recurrent disease, especially for some subtypes of EOC (e.g., low-grade serous EOC). Furthermore, HT has recently been combined with targeted therapies, but most studies evaluating these combinations are still ongoing. The main aim of this review is to provide an overview of the progress made in the last decade to characterize the biological and prognostic role of HRs for EOC and the developments in their therapeutic targeting through HT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Biomedicines - 11(2023), 8 vom: 01. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Borella, Fulvio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aromatase inhibitors |
|---|
| Anmerkungen: |
Date Revised 19.09.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/biomedicines11082157 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361248350 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361248350 | ||
| 003 | DE-627 | ||
| 005 | 20231226084737.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/biomedicines11082157 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361248350 | ||
| 035 | |a (NLM)37626654 | ||
| 035 | |a (PII)2157 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Borella, Fulvio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hormone Receptors and Epithelial Ovarian Cancer |b Recent Advances in Biology and Treatment Options |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.09.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Epithelial ovarian cancer (EOC) is a significant cause of cancer-related mortality in women. Despite advances in diagnosis and treatment, EOC remains a challenging disease to manage, and the 5-year survival rate is still poor. The role of hormone receptors (HRs) in EOC carcinogenesis and prognosis has been actively explored; however, the role of hormone therapy (HT) in the treatment of these tumors is not well established. Most available data on HT mainly come from retrospective series and small early clinical trials. Several of these studies suggest that HT may have a role in adjuvant, maintenance therapy, or in the case of recurrent disease, especially for some subtypes of EOC (e.g., low-grade serous EOC). Furthermore, HT has recently been combined with targeted therapies, but most studies evaluating these combinations are still ongoing. The main aim of this review is to provide an overview of the progress made in the last decade to characterize the biological and prognostic role of HRs for EOC and the developments in their therapeutic targeting through HT | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a aromatase inhibitors | |
| 650 | 4 | |a endocrine therapy | |
| 650 | 4 | |a fulvestrant | |
| 650 | 4 | |a hormone receptors | |
| 650 | 4 | |a hormone therapy | |
| 650 | 4 | |a letrozole | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a tamoxifen | |
| 700 | 1 | |a Fucina, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Mangherini, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Cosma, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Carosso, Andrea Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Cusato, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Cassoni, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Bertero, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Katsaros, Dionyssios |e verfasserin |4 aut | |
| 700 | 1 | |a Benedetto, Chiara |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicines |d 2013 |g 11(2023), 8 vom: 01. Aug. |w (DE-627)NLM268899797 |x 2227-9059 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:8 |g day:01 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/biomedicines11082157 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 8 |b 01 |c 08 | ||